资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

[The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].

Sichuan Da Xue Xue Bao Yi Xue Ban. 2019-03;

ChenYue，MoZe-Ming，QinDi-Yuan，GuoFu-Chun，LiaoXue-Lian，HuMin，ChenQian，WangYong-S

Products/Services Used	Details	Operation
Catalog Antibody	… 177 5.3.2 AIM 2: CDC ACTIVITY OF FPLC-PURIFIED SA1 ANTIBODY ..... 189 5.3.3 AIM 3: SA1 HUMANISATION (IN COLLABORATION WITH GENSCRIPT) .... 192 5.4 DISCUSSION..... 203 …	Get A Quote

摘要

To test the killing effect of type Ⅰ receptor tyrosine kinase-like orphan receptor (ROR1) chimeric antigen receptor T cell (CAR-T) on several ROR1-expressing tumor cells